Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

724
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

640
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
640
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

614
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicted adherence and ischaemic stroke risk in atrial fibrillation patients initiating oral anticoagulation: A cohort study of the medication adherence score.

International journal of cardiology·2026
Same author

The Predictive Value of Impedance for Defibrillation Success After S-ICD Implantation: A Reliable Indicator?

JACC. Clinical electrophysiology·2026
Same author

Comparison of Two Pulsed Field Ablation Systems for Atrial Fibrillation: One-Year Outcomes From a Multicenter Registry.

Journal of cardiovascular electrophysiology·2026
Same author

Artificial intelligence vs electrophysiologist adjudication of atrial arrhythmias.

Heart rhythm·2026
Same author

Safety, performance, and remote programming utilization of an insertable cardiac monitor: The LUX-Dx PERFORM study.

Heart rhythm O2·2026
Same author

Subcutaneous Defibrillator Implantation With or Without Defibrillation Test: The Primary Results of the Randomized PRAETORIAN-DFT Trial.

Circulation·2026

Related Experiment Video

Updated: Apr 18, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

27.0K

A new algorithm to reduce inappropriate therapy in the S-ICD system.

Amy J Brisben1, Martin C Burke2, Bradley P Knight3

  • 1Boston Scientific Corporation, St. Paul, Minnesota, USA.

Journal of Cardiovascular Electrophysiology
|January 13, 2015
PubMed
Summary

A new algorithm for subcutaneous implantable cardioverter-defibrillator (S-ICD) systems significantly reduces T-wave oversensing (TWOS) by approximately 40%. This innovation aims to decrease inappropriate shocks in patients at risk for sudden cardiac death.

Keywords:
S-ICDT-wave oversensingalgorithminappropriate shockssubcutaneous implantable cardioverter defibrillator

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

27.0K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.8K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Subcutaneous implantable cardioverter-defibrillator (S-ICD) systems are effective for sudden cardiac death prevention.
  • While reliable for ventricular tachyarrhythmias, S-ICD systems experience higher T-wave oversensing (TWOS) than transvenous systems.
  • TWOS can lead to inappropriate shocks, necessitating improved detection algorithms.

Purpose of the Study:

  • To develop and validate a novel discrimination algorithm for S-ICD systems.
  • The primary goal was to reduce TWOS events without compromising the detection of life-threatening ventricular arrhythmias.
  • To enhance the clinical utility of S-ICD therapy by minimizing inappropriate shocks.

Main Methods:

  • Algorithm development involved a database of recorded S-ICD episodes, including ventricular arrhythmias and TWOS events.
  • A computer model simulating the S-ICD system was used for initial development.
  • Algorithm validation was performed on actual device hardware using an independent dataset of TWOS, ventricular, and supraventricular episodes.

Main Results:

  • The novel algorithm demonstrated a reduction in inappropriate charges due to TWOS by 30.7% during development.
  • Independent validation showed the algorithm avoided inappropriate charges due to TWOS by 39.8%.
  • No compromise in sensitivity for ventricular arrhythmias or significant change in specificity for supraventricular arrhythmias was observed.

Conclusions:

  • A new S-ICD algorithm utilizing complex waveform correlation effectively reduces TWOS episodes by approximately 40%.
  • This algorithm shows significant potential for a clinically meaningful reduction in inappropriate shocks for S-ICD patients.
  • The findings support the integration of this algorithm to improve S-ICD system performance and patient safety.